Form 4: Fulgent Genetics Chief Scientific Officer Sells Shares for Tax Obligations Under 10b5-1 Plan
Insider Transaction Report
Fulgent Genetics' Chief Scientific Officer, Hanlin Gao, sold 754 shares of common stock on June 2, 2025, to cover tax withholding obligations related to the vesting of restricted stock units.
Summary
- Hanlin Gao, Chief Scientific Officer of Fulgent Genetics, Inc. (FLGT), disposed of 754 shares of common stock.
- The transaction occurred on June 2, 2025, at a weighted-average sale price of $20.2908 per share.
- The sale was conducted to satisfy tax withholding obligations arising from the vesting of restricted stock units (RSUs) granted on February 28, 2022.
- The transaction was made pursuant to a Rule 10b5-1(c) pre-arranged trading plan.
- Following this transaction, Mr. Gao beneficially owns 961,281 shares of Fulgent Genetics common stock.
Sentiment
Score: 5
Explanation: The transaction is a routine sale to cover tax obligations upon RSU vesting, which is a common practice and does not indicate a change in management's confidence or company performance. The transaction was also conducted under a Rule 10b5-1 plan, indicating it was pre-scheduled.
Positives
- The sale indicates the vesting of restricted stock units, which is a positive event for the employee as it represents earned compensation.
Negatives
- The sale of shares by an insider, even for tax purposes, reduces their direct ownership stake in the company.
Future Outlook
The document does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.
Management Comments
- The shares were sold from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 28, 2022.
Industry Context
This Form 4 filing reports a routine insider transaction related to executive compensation and tax obligations, which is common across all industries, including the biotechnology and genetics sector where Fulgent Genetics operates. It does not provide insights into broader industry trends.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Trading Plan Disclosure | The transaction was made pursuant to a Rule 10b5-1(c) contract, instruction, or written plan for the purchase or sale of equity securities, which provides an affirmative defense against insider trading allegations. | June 2, 2025 | This indicates a pre-arranged trading strategy, enhancing transparency and reducing the perception of opportunistic insider trading. |
Stakeholder Impact
- Shareholders: The sale is a minor, routine transaction and is unlikely to have a significant direct impact on existing shareholders.
- Employees: The vesting of RSUs and subsequent sale for tax purposes is a standard component of executive compensation, reflecting the fulfillment of long-term incentive plans.
Key Dates
| Date | Description |
|---|---|
| February 28, 2022 | Date restricted stock units (RSUs) were granted to the reporting person. |
| March 2, 2022 | Date original Form 4 was filed regarding the RSU grants. |
| June 2, 2025 | Date of the reported transaction (sale of common stock). |
| June 3, 2025 | Date the Form 4 was signed and filed. |
Keywords
Fulgent Genetics, FLGT, Form 4, Insider Trading, Stock Sale, Restricted Stock Units, Tax Withholding, Hanlin Gao, Chief Scientific Officer, Biotechnology, Genetics, 10b5-1 Plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.